Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOXIRI-3 in elderly or frail advanced pancreatic adenocarcinoma
NCT03974854Phase 2Terminated
- Sponsor
- CHU de Besançon
- Start
- Jul 2019
- Primary completion
- Aug 2023
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, oxaliplatin, irinotecan in pancreatic ductal adenocarcinoma (PDAC), sponsored by CHU de Besançon. Started Jul 2019; status: terminated.
02
Drugs
capecitabineoxaliplatinirinotecan
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03974854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03974854.